A Cyclic Peptide‐Based Radiotheranostic Agent for Urokinase‐Type Plasminogen Activator in Tumors
Chemistry – A European Journal · 2025
DOI: 10.1002/chem.202500479 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, 2025. Verfasst von Xingkai Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and P…. Hauptthemen laut MEDLINE: Urokinase-Type Plasminogen Activator, Peptides, Cyclic, Radiopharmaceuticals, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Nonprofit Central Research Institute Fund of the Chinese Academy of Medical Sciences, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
The plasminogen activator system is critically involved in tumor progression regulation. Aberrant activation of urokinase‐type plasminogen activator (uPA) induces proteolytic degradation of cellular membranes and the extracellular matrix, thereby promoting tumor invasion and metastasis. Consequently, uPA has emerged as a promising diagnostic and therapeutic target. Herein, we designed and evaluated three cyclic peptide‐based radioligands ([⁶⁴Cu]CAP‐1, [⁶⁴Cu]CAP‐2, and [⁶⁴Cu]CAP‐3) as potential PET tracers for uPA visualization in mouse tumor models, assessing their binding ability, specificity, and pharmacokinetic profiles. Among them, [⁶⁴Cu]CAP‐1, featuring a native disulfide bond, emerged as the optimal candidate. This radioligand demonstrated superior tumor uptake and reduced hepatic accumulation compared to the clinically advanced uPAR‐targeted tracer [⁶⁴Cu]DOTA‐AE105, currently in Phase 2 trials. A single administration of [⁶⁴Cu]CAP‐1 (2 mCi/mouse) significantly suppressed tumor growth and prolonged survival in mouse models. These findings position [⁶⁴Cu]CAP‐1 as a potent radiotheranostic agent for uPA‐overexpressing tumors, offering a novel strategy for precision targeting of the uPA/uPAR axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Xian Nong Tan Street, Beijing, China.
- Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Cl…
- Department of Molecular Medicine, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin, China.
- Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
- Department of Orthopaedics, the Second Affiliated Hospital of Soochow University, Suzhou, China.
ORCID-Profile: Kuan Hu
Förderung
- National Natural Science Foundation of China
- Nonprofit Central Research Institute Fund of the Chinese Academy of Medical Sciences
- CAMS Innovation Fund for Medical Sciences
- Beijing Nova Program and Beijing Nova Program Interdisciplinary Cooperation Project
- Beijing Natural Science Foundation
- Fundamental Research Funds for the Central Universities
- CIRP Open Fund of Radiation Protection Laboratories
- China National Nuclear Corporation Young Talent Program
Zitieren
APA
Wang, X., Dai, D., Shen, J., Zhang, S., Ohkubo, T., Xie, L., Zhang, Y., Li, G., Liu, C., Tian, H., Zhang, Y., Zhang, M. R., Wang, R., & Hu, K. (2025). A Cyclic Peptide‐Based Radiotheranostic Agent for Urokinase‐Type Plasminogen Activator in Tumors. Chemistry – A European Journal. https://doi.org/10.1002/chem.202500479
Vancouver
Wang X, Dai D, Shen J, Zhang S, Ohkubo T, Xie L, et al. A Cyclic Peptide‐Based Radiotheranostic Agent for Urokinase‐Type Plasminogen Activator in Tumors. Chemistry – A European Journal. 2025. doi:10.1002/chem.202500479
BibTeX
@article{Wang2025,
author = {Wang, Xingkai and Dai, Dong and Shen, Jieting and Zhang, Siqi and Ohkubo, Takayuki and Xie, Lin and Zhang, Yiding and Li, Guoqing and Liu, Can and Tian, Hao and Zhang, Yingzi and Zhang, Ming-Rong and Wang, Rui and Hu, Kuan},
title = {A Cyclic Peptide‐Based Radiotheranostic Agent for Urokinase‐Type Plasminogen Activator in Tumors},
journal = {Chemistry – A European Journal},
year = {2025},
doi = {10.1002/chem.202500479}
}
EUVIMED